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Summary
Background Germline pathogenic variants in the E-cadherin gene (CDH1) are strongly associated with the 
development of hereditary diffuse gastric cancer. There is a paucity of data to guide risk assessment and 
management of families with hereditary diffuse gastric cancer that do not carry a CDH1 pathogenic variant, 
making it difficult to make informed decisions about surveillance and risk-reducing surgery. We aimed to identify 
new candidate genes associated with predisposition to hereditary diffuse gastric cancer in affected families without 
pathogenic CDH1 variants.
Methods We did whole-exome sequencing on DNA extracted from the blood of 39 individuals (28 individuals 
diagnosed with hereditary diffuse gastric cancer and 11 unaffected first-degree relatives) in 22 families without 
pathogenic CDH1 variants. Genes with loss-of-function variants were prioritised using gene-interaction analysis to 
identify clusters of genes that could be involved in predisposition to hereditary diffuse gastric cancer.
Findings Protein-affecting germline variants were identified in probands from six families with hereditary diffuse 
gastric cancer; variants were found in genes known to predispose to cancer and in lesser-studied DNA repair genes. 
A frameshift deletion in PALB2 was found in one member of a family with a history of gastric and breast cancer. 
Two different MSH2 variants were identified in two unrelated affected individuals, including one frameshift insertion 
and one previously described start-codon loss. One family had a unique combination of variants in the DNA repair 
genes ATR and NBN. Two variants in the DNA repair gene RECQL5 were identified in two unrelated families: 
one missense variant and a splice-acceptor variant.
Interpretation The results of this study suggest a role for the known cancer predisposition gene PALB2 in families 
with hereditary diffuse gastric cancer and no detected pathogenic CDH1 variants. We also identified new candidate 
genes associated with disease risk in these families.
Funding UK Medical Research Council (Sackler programme), European Research Council under the European 
Union’s Seventh Framework Programme (2007–13), National Institute for Health Research Cambridge Biomedical 
Research Centre, Experimental Cancer Medicine Centres, and Cancer Research UK.
Copyright © The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY 4.0 license.
Introduction
Gastric cancer is the fourth most common cancer globally. 
The best characterised inherited gastric cancer is the 
diffuse type, which has the hallmark of multiple foci of 
signet-ring cells.1 The term hereditary diffuse gastric 
cancer is used to describe families with a history of diffuse 
gastric cancer that meet the criteria of at least two cases of 
gastric cancer in first-degree or second-degree relatives 
regardless of age of onset (with one confirmed case of 
diffuse gastric cancer); one case of diffuse gastric cancer 
diagnosed before age 40 years; or a personal or family 
history of diffuse gastric cancer and lobular breast cancer, 
including one case diagnosed before age 50 years.2,3
Germline mutations in the E-cadherin gene (CDH1) 
explain 25–30% of hereditary diffuse gastric cancer 
cases, with more than 100 pathogenic germline variants 
currently described within this gene.4 For families with 
hereditary diffuse gastric cancer and known pathogenic 
CDH1 mutations, guidelines exist for risk assessment, 
disease management, surveillance (including regular 
endoscopies), and risk-reducing therapies (including 
prophylactic gastrectomy).5,6 However, for families with 
no pathogenic variant in CDH1, the risk assessment 
is uncertain and, therefore, making decisions about 
and assessing the efficacy of risk-reducing strategies 
is challenging.
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Other familial cancer syndromes that have been 
linked to gastric cancer predisposition include Lynch 
syndrome, which is characterised by mutations in DNA 
mismatch repair genes; Peutz-Jeghers syndrome caused 
by mutations in STK11; and Li-Fraumeni syndrome, 
which is associated with germline TP53 mutations.2,7–9 
Diffuse gastric cancer does not appear to be 
over-represented in these syndromes, although this 
association has not been comprehensively studied.
Predicted pathogenic variants in the DNA double-strand 
break repair genes ATM, BRCA2, and PALB2 have been 
identified in several families with hereditary diffuse gastric 
cancer.4,10 However, given the rarity of these variants, the 
associated risk of diffuse gastric cancer is hard to quantify, 
and these variants are not used in routine clinical testing to 
aid management of these families.
We aimed to identify new candidate genes for 
predisposition to hereditary diffuse gastric cancer in 
families without pathogenic CDH1 variants.
Methods
Study design and participants
In this whole-exome sequencing study, we recruited 
28 individuals diagnosed with diffuse gastric cancer and 
11 unaffected relatives from 22 families with hereditary 
diffuse gastric cancer that had tested negative for CDH1 
pathogenic germline mutations as part of the Familial 
Gastric Cancer study (MREC 97/5/32) and for whom 
blood and tumour samples were available. Families 
(including first-degree and second-degree relatives) were 
categorised as having hereditary diffuse gastric cancer on 
the basis of existing criteria.2,3,6
Whole-exome sequencing and variant filtering
DNA was extracted from blood or saliva and prepared 
for 125-bp paired-end whole-exome sequencing using 
the Nextera Rapid Capture Exome Enrichment Kit 
(Illumina, San Diego, CA, USA). Sequencing was done 
on HiSeq-4000 or HiSeq-2500 platforms (Illumina, 
San Diego, CA, USA). Variant Call Format files were 
generated with a standard pipeline following Genome 
Analysis Toolkit (GATK) Best Practices recommendations 
for whole-exome data (appendix). The dataset was filtered 
to select uncommon (allele frequency <0·05 in the 
1000 Genomes Project European sample) protein-affecting 
variants, including loss-of-function variants (stop site 
gained, stop site lost, start site lost, splice acceptor, splice 
donor, or frameshift), deleterious (predicted with Sorting 
Intolerant From Tolerant version 5.2.2) and damaging 
(predicted with Polymorphism Phenotyping version 2.2.2) 
missense variants, and inframe indels, that were observed 
in at least one of the 28 affected individuals. These filters 
were chosen to remove variants that were least likely to 
affect predisposition to hereditary diffuse gastric cancer. 
We considered the 11 unaffected family members 
separately on a per-family basis as a control group on 
which we did segregation analysis for identified candidate 
variants. We determined the allele frequency of all 
candidate variants in healthy controls (with no history of 
cancer) and allele counts in affected and unaffected 
individuals within families, and predicted downstream 
effects on the protein product.
Variants were aggregated into unique genes, which 
were then filtered to select those that contained at least 
one loss-of-function variant. We also removed the top 1% 
Research in context
Evidence before this study
Knowledge of factors causing predisposition to hereditary diffuse 
gastric cancer in families with no pathogenic variants in CDH1 is 
limited by the rarity of the disease, which makes doing large-scale 
association studies difficult. In 2015, Hansford and colleagues 
described variants in DNA repair-related genes in 144 families 
with hereditary diffuse gastric cancer without CDH1 pathogenic 
variants. These genes included PALB2, BRCA2, and ATM, which 
are associated with breast cancer risk. Further investigation of 
these genes, other known cancer-predisposing genes, and genes 
associated with DNA repair will aid in the disease management of 
families with hereditary diffuse gastric cancer without CDH1 
pathogenic variants, whose risk of disease development is 
currently unknown.
Added value of this study
This study is one of the largest germline, whole-exome 
sequencing analysis of families with hereditary diffuse gastric 
cancer without CDH1 mutation to date. Both affected and 
unaffected individuals were recruited from families with 
hereditary diffuse gastric cancer, providing the opportunity to 
look for protein-affecting variants that segregate with 
phenotype. We used a unique approach to pathway analysis that 
involved clustering of physically interacting genes that were 
enriched for variants in these families and annotating them with 
a Gene Ontology term. Additionally, combining findings from 
this study with data from previously published studies allowed a 
more complete analysis of the role of the cancer predisposition 
genes PALB2 and BRCA2.
Implications of all the available evidence
We identified a cluster of interacting genes involved in DNA 
repair that could be associated with predisposition to hereditary 
diffuse gastric cancer, in particular, PALB2. These findings should 
help guide future studies seeking to elucidate the clinical 
implications of genes that have not been previously associated 
with hereditary diffuse gastric cancer. Identification of these 
genes could provide families with hereditary diffuse gastric 
cancer without CDH1 pathogenic variants with improved 
information about the risks associated with their disease and 
allow them to make informed decisions about risk reduction 
and disease management.
For more on Sorting Intolerant 
From Tolerant see 
http://sift.bii.a-star.edu.sg
For more on Polymorphism 
Phenotyping see 
http://genetics.bwh.harvard.
edu/pph2
For more on the 1000 Genomes 
Project see http://www.
internationalgenome.org
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most variable genes, which were identified by the 
number of rare, protein-affecting variants per gene. These 
genes typically possess many rare variants within the 
healthy population and, therefore, are unlikely to have a 
role in predisposition to hereditary diffuse gastric cancer 
or other diseases. Variant-filtering and gene-filtering steps 
are summarised in the appendix.
To analyse copy number variants, we applied the 
XHMM algorithm to the gene set, using principle 
component analysis to normalise read depth across 
exomes and a hidden Markov model to identify regions 
with variation in read depth.11 Around a 50% decrease or 
increase in read depth was required for the variant to be 
considered for further analysis. Copy number variants 
were further explored in selected individuals with a 
CytoScan 750K genotyping array (Affymetrix, Santa Clara, 
CA, USA), according to the clinical protocol.
The results published here are in whole or part based 
on data generated by The Cancer Genome Atlas (TCGA), 
managed by the National Cancer Institute and the 
National Human Genome Research Institute. Controlled 
access data was requested and downloaded for the 
TCGA-STAD dataset, of which a subset of data from 
88 cases of diffuse gastric cancer were analysed to further 
validate the role of the identified candidate genes in 
predisposition to diffuse gastric cancer.
Gene-interaction network analysis
Gene-interaction network analysis was used to identify 
variant-enriched candidate genes with interacting 
protein products; non-antagonistic, physically interacting 
proteins might have a similar effect on cell function and, 
therefore, might produce a shared phenotype when 
mutated. The filtered genes were put through the 
GeneMANIA Cytoscape plugin version 3.4.1, which 
places physically interacting genes into clusters.12 
A cluster was defined as a set of five or more physically 
interacting genes.
We used the PANTHER over-representation test 
(version 13.0) in the Gene Ontology Consortium 
enrichment analysis web-tool to assign Gene Ontology 
(GO) terms to clusters, applying the default Bonferroni 
correction for multiple testing.13 Of the significant terms 
highlighted in the analysis, the most significant term 
that encompassed between ten and 200 genes was 
selected, consistent with previous studies.14
Allelic counts of all filtered, loss-of-function variants 
within the selected GO terms (regardless of GeneMANIA 
Cytoscape clustering) were aggregated and contingency 
tables were drawn. Variants were also aggregated for 
each GO term over a comparably filtered set of genes 
from 503 European individuals in phase 3 of the 
1000 Genomes study (appendix).15 We did a one-tailed 
Fisher’s exact test using the R Stats package version 3.3.3 
to test for enrichment of loss-of-function variants within 
each selected GO term in the families with hereditary 
diffuse gastric cancer compared with the 1000 Genomes 
European dataset. For this test, only one occurrence of a 
variant was counted per affected family. A link to the 
custom R scripts used for this analysis can be found in 
the appendix.
Validation by Sanger sequencing
Candidate variants were validated by Sanger sequencing. 
Germline DNA from blood and extracted tumour DNA 
were quantified with the Qubit dsDNA HS Kit 
(Invitrogen, Carlsbad, CA, USA), and custom flanking 
primers were designed for each variant (primer 
sequences are shown in the appendix). DNA fragments 
were amplified by PCR and the products were sequenced 
on an ABI Genetic Analyser (Applied Biosystems Foster 
City, CA, USA) with BigDye Terminator version 3.1 
(Invitrogen, Carlsbad, CA, USA), according to the 
manufacturer’s instructions.
Tumour immunohistochemistry and microsatellite 
instability analysis
We used the Ventana MMR IHC Panel (Roche, 
Indianapolis, IN, USA) to do immunohistochemistry 
analysis of known mismatch repair genes in available 
tumours from individuals in which variants in mismatch 
repair genes were identified. The panel includes 
antibodies against MLH1, PMS2, MSH2, and MSH6.
To analyse microsatellite instability, 5-µm formalin-
fixed, paraffin-embedded tumour sections were mounted 
on glass slides for dewaxing and manual microdissection. 
DNA was extracted with the QIAamp DNA FFPE Tissue 
Kit (Qiagen, Hilden, Germany). We assessed the DNA 
for five standard microsatellite markers (BAT25, BAT26, 
NR21, NR24, and MONO27) using the Promega MSI 
Analysis System, version 1.2 (Promega, Madison, WI, 
USA). Poorly and moderately differentiated gastric tissue 
was compared with adjacent tumour-free tissue.
Analysis of PALB2 and BRCA2 variants in published studies
We searched PubMed without language restrictions 
between Jan 1, 2015, and Dec 31, 2017, using the term 
“hereditary diffuse gastric cancer” to identify sequencing 
studies reporting loss-of-function variants in PALB2 and 
BRCA2 in hereditary diffuse gastric cancer probands with 
no detected pathogenic CDH1 variants. We included only 
publications released after the initial report4 in 2015 of 
PALB2 and BRCA2 mutations associated with hereditary 
diffuse gastric cancer. For each of the four identified 
publications4,10,16,17 and this study, we aggregated the allele 
counts of loss-of-function PALB2 variants. The same 
counts were done across the 503 European samples from 
the 1000 Genomes Project and the 27 173 non-Finnish 
European individuals not in the TCGA from the Exome 
Aggregation Consortium (ExAC) control datasets.18 We 
removed the well characterised, non-pathogenic BRCA2 
polymorphic stop codon in c.9976A→T from all datasets. 
We did a one-tailed Fisher’s exact test using the R Stats 
package version 3.3.3 to test for enrichment of 
For more on The Cancer 
Genome Atlas see 
http://cancergenome.nih.gov
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loss-of-function PALB2 or BRCA2 variants in the families 
with hereditary diffuse gastric cancer compared with 
either control dataset.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
Article. EF, JR, and MT had access to the raw data. 
The corresponding author had full access to all of the 
data and the final responsibility for the decision to 
submit for publication.
Results 
A whole-exome sequencing dataset of 39 individuals 
from 22 families with hereditary diffuse gastric 
cancer without pathogenic CDH1 variants (table 1) was 
filtered to select 3973 uncommon, protein-affecting 
variants that were aggregated into 2847 genes. Exclusion 
of the top 1% of highly variable genes, and retention of 
genes with at least one loss-of-function variant in 
affected individuals, resulted in a set of 732 genes 
(1228 variants). Eight highly variable genes were 
excluded, including ANKRD36, CDC27, HLA-DRB1, 
HLA-DRB5, MUC3A, MUC4, MUC6, and OR4C5. 
Additionally, the presence of affected and unaffected 
family members within our dataset allowed for selection 
Number of samples 
sequenced*
Age of proband at 
diagnosis (years)
Cancers diagnosed in relatives of probands† Candidate 
gene identified 
in proband
Affected Unaffected
1 2 0 41 Diffuse gastric cancer (44)‡, gastric cancer (57) None
2 2 4 27 Peritoneal cancer, ovarian cancer (22), diffuse gastric cancer (24)‡, diffuse gastric cancer (28) None
3 1 0 40 Gastric cancer (28), diffuse gastric cancer (48) None
4 1 2 55 Breast cancer, lung cancer, laryngeal cancer, gastric cancer, and diffuse gastric cancer (44, 52) PALB2
5 1 0 36§ Diffuse gastric cancer (37), lung cancer (54), colorectal cancer (57), breast cancer (50), diffuse 
gastric cancer (61), diffuse gastric cancer (79), lung cancer (83)
None
6 1 0 37 Breast cancer, gastric cancer (63), gastric cancer (64) RECQL5
7 2 0 36 Colorectal cancer, breast cancer (43), diffuse gastric cancer (55)‡ None
8 1 0 47¶ Diffuse gastric cancer (44) MSH2||
9 1 0 44 Diffuse gastric cancer (28) None
10 1 2 28 Breast cancer, gastric cancer (44), gastric cancer (47) None
11 4 1 28 Signet-ring cells‡, Signet-ring cells‡, breast cancer (40s), diffuse gastric cancer (45)‡, 
prostate cancer (60s), colorectal cancer (75)
ATR, NBN
12 1 0 68 Lung cancer, gastric cancer (49), gastric cancer (50), gastric cancer (76) MSH2||
13 1 0 47 Gastric cancer, gastric cancer (50s), gastric cancer (60s) None
14 1 0 23 Diffuse gastric cancer (40s), diffuse gastric cancer (46), thyroid cancer (30) None
15 1 0 53 Gastric cancer (49), gastric cancer (67), gastric cancer (71) None
16 1 0 37 Gastric cancer, breast cancer (54), breast cancer (65), colorectal cancer (66) None
17 1 0 45 Diffuse gastric cancer (42) None 
18 1 0 48 Gastric cancer (44), gastric cancer (54) None
19 1 1 35 Lung cancer, uterine cancer (65) None
20 1 0 55 Gastric cancer (51), colorectal cancer (76) None 
21 1 1 28 Gastric cancer (53), breast cancer (76), gastric cancer (80) RECQL5
22 1 0 30 Gastric cancer, diffuse gastric cancer (67) None 
In total, 39 individuals were sequenced, including 11 unaffected relatives. Numbers in parentheses indicate age in years at diagnosis. *All probands were sequenced in this study. 
†Includes both first-degree and second-degree relatives; age in years at diagnosis is in parentheses when known. ‡Sequenced in this study. §This proband was also diganosed 
with colorectal cancer at age 47 years. ¶This proband was also diagnosed with lobular breast cancer at age 36 years. ||No microsatellite instability was detected in tumour. 
Table 1: Characteristics of 28 affected individuals in 22 families with hereditary diffuse gastric cancer without CDH1 pathogenic variants
Figure 1: Gene clusters identified via gene interaction analysis
Lines indicate a physical interaction, as assigned by the GeneMANIA plugin for Cytoscape.12 (A) Gene cluster to 
which the double-strand break repair GO term (GO:0006302) was assigned. (B) Gene cluster to which the negative 
regulation of extrinsic apoptotic signalling pathway via death domain receptors GO term (GO:1902042) was 
assigned. GO=Gene Ontology.
CASP8 GRIA1
LIMS1
PASK
DCTN1 FGA
TNFRSF10B
MAPT
ACIN1
MAP2K3
PRKDC
ATR
BRCA2
CEP164
NBN
RECQL5 PALB2
MSH2
A B
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of variants that segregated with phenotype on a 
per-family basis.
Gene-interaction network analysis of the 732 filtered 
genes identified two physical interaction clusters, to 
which GO terms were applied (figure 1). A cluster of 
eight genes was associated with the GO term 
double-strand break repair (GO:0006302; p<0·0001; 
figure 1A). A second cluster of ten genes was associated 
with the GO term negative regulation of extrinsic 
apoptotic signalling pathway via death domain receptors 
(GO:1902042; p=0·00517; figure 1B).
Loss-of-function variants within the filtered set of 
1228 variants were aggregated under these two GO terms, 
including genes related to the GO terms that were not 
initially clustered by GeneMANIA. The double-strand 
break repair term was significantly enriched in families 
with hereditary diffuse gastric cancer compared with the 
1000 Genomes European set (p=0·00051). By contrast, the 
apoptotic signalling pathway term was not enriched in 
families with hereditary diffuse gastric cancer (p=0·186), 
suggesting that the differences between the datasets in 
allele counts of DNA double-strand break repair genes 
cannot entirely be explained by technical differences that 
arise when using an externally produced control dataset.
Genes in the double-strand break repair GO term 
included PALB2, MSH2, RECQL5, ATR, and NBN, all of 
which were shown to be physically interacting in 
GeneMANIA (figure 1A). BRCA2 was also a part of this 
set, but was disregarded from further study because it 
contained the well characterised, benign polymorphic 
stop codon c.9976A→T.19
Table 2 summarises the candidate variants. A 
heterozygous 2 bp frameshift deletion was identified in 
PALB2 (c.757-758TAG→T [rs180177092, NM_024675.3]) 
in a patient from family 4 who was diagnosed with 
diffuse gastric cancer at age 55 years (figure 2). This 
loss-of-function variant at aminoacid position 253 is 
predicted to result in an early stop codon seven aminoacids 
downstream of the variant. Family 4 has a history of 
breast, lung, laryngeal, and diffuse gastric cancer 
(table 1, figure 2). Exome sequencing was also done on 
two unaffected siblings, one of whom also had the PALB2 
(c.757-758TAG→T [rs180177092, NM_024675.3]) variant. 
The affected proband had previously received treatment 
for Helicobactor pylori infection, but had tested negative at 
subsequent endoscopies.
Two heterozygous loss-of-function variants were 
identified in the mismatch repair gene MSH2: a start 
site loss (c.1A→C [rs267607911, NM_000251.2]) in a 
patient from family 12 and a frameshift insertion of 
4 bp (c.967-968T→TCTCA [NM_000251.2]) in a patient 
from family 8 (table 2; appendix). Both families had a 
strong history of gastric cancer; however, only DNA 
from the probands was available for sequencing, so 
segregation analysis could not be done. Heterozygosity 
of both variants was maintained in tumour DNA 
from the patients, as confirmed by Sanger sequencing. 
Tumours from both probands showed normal 
expression of MSH2 and other mismatch repair 
proteins by immunohistochemistry compared with 
adjacent tumour-free tissue (appendix), and neither 
tumour showed evidence of microsatellite instability 
(appendix). Both probands with MSH2 variants had 
previously tested negative for H pylori.
Heterozygous variants in the DNA repair genes ATR 
and NBN—a splice-donor variant (c.1124+1G→C 
[NM_002485.4]) in NBN and a predicted stop site-gain 
variant (c.6075A→T [NM_001184.3]) in ATR—were 
identified in the proband from family 11, who was 
diagnosed with diffuse gastric cancer at age 28 years 
(figure 3, table 2). Two siblings underwent risk-reducing 
gastrectomies, and subsequent pathological analysis of 
gastric tissue revealed the presence of signet-ring cells 
in both individuals. As such, these individuals were 
considered to be affected family members in this 
analysis. The father of the proband was diagnosed with 
diffuse gastric cancer at age 60 years and the mother had 
metastatic disease characterised by signet-ring cells, 
Number of 
sequenced 
individuals
Gene Variant Consequence Protein change Minimum allele frequency SIFT Polymorphism 
Phenotyping
1000 Genomes 
European sample
ExAC non-TCGA 
European sample
4 3 PALB2 c.757-758TAG→T Frameshift deletion Leu253fs 0 0 NA NA
6 1 RECQL5 c.2806-2T→C Splice-acceptor variant NA 0 0 NA NA
8 1 MSH2 c.967-968T→TCTCA Frameshift insertion Ser323fs 0 0 NA NA
11 5 ATR c.6075A→T Stop site gain Tyr2025X 0 0 NA NA
11 5 NBN c.1124+1G→C Splice-donor variant NA 0 0 NA NA
12 1 MSH2 c.1A→C Start site loss Met1?* 0 0 Deleterious Benign
21 2 RECQL5 c.2828C→T Missense variant Arg943His 0·002 0·014332 Deleterious Probably damaging
SIFT=Sorting Intolerant From Tolerant. ExAC=Exome Aggregation Consortium. TCGA=The Cancer Genome Atlas. fs=frameshift. NA=not applicable. *Human Genome Variation Society nomenclature to indicate loss of 
a start site without experimental evidence of a new start site.20
Table 2: Candidate variants in six families with hereditary diffuse gastric cancer without CDH1 pathogenic variants
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which suggests that she had primary gastric cancer. 
All individuals in this family whose DNA was sequenced 
tested negative for H pylori. The proband and both 
siblings were heterozygous for loss-of-function variants 
in both ATR and NBN. The splice-donor variant in NBN 
was not seen in the father, and so was presumed to have 
been inherited maternally (DNA was only available for 
the father). The ATR variant was identified in the father, 
in whom no clinically relevant copy number variants 
were found. An unaffected, second-degree relative in 
family 11 did not have either variant.
Two variants were identified in the helicase gene 
RECQL5 in different families. One was a missense 
variant (c.2828C→T [rs200535477, NM_004259.6]) in 
the proband from family 21, who was diagnosed with 
diffuse gastric cancer at age 28 years, and the other was 
a loss-of–function, splice-acceptor variant (c.2806-2T→C 
[rs201841487, NM_004259.6]) in the proband from 
family 6, who was diagnosed with diffuse gastric cancer 
at age 37 years (table 2; appendix). Both of these families 
included individuals across three generations who 
were diagnosed with gastric cancer and breast cancer. 
The proband of family 6 tested negative for H pylori, and 
the H pylori status of the proband from family 21 was 
unknown. DNA from the father of the proband in 
family 21 was sequenced, and the missense variant in 
RECQL5 was not found.
We did not explore variants in other genes within the 
double-strand break repair cluster because the variants 
did not segregate with the disease in families containing 
affected and unaffected members.
We analysed data from previous studies4,10,16,17 to 
estimate enrichment of loss-of-function variants in 
PALB2 and BRCA2 in families with hereditary diffuse 
gastric cancer. A loss-of-function variant (c.1438A→T 
[rs1057520653, NM_024675.3]) was identified and 
reported to us by collaborators (Teixeira MR, 
unpublished), however this variant was not included in 
the analysis because it did not fit our search criteria. 
Five (2%) of the 329 probands tested in these studies 
(including the present study) had loss-of-function 
PALB2 variants (table 3). By contrast, PALB2 variants 
were identified in 26 (<1%) of 27 173 individuals in the 
non-TCGA, non-Finnish European ExAC database 
(p<0·0001) and in one (<1%) of 503 individuals in the 
1000 Genomes Project European database (p=0·039). 
Loss-of-function BRCA2 variants were not enriched in 
families with hereditary diffuse gastric cancer compared 
with ExAC (p=0·47) or 1000 Genomes Project (p=1·00) 
individuals. No loss-of-function PALB2 variants were 
identified in a set of 88 cases with sporadic diffuse 
gastric cancer from the TCGA.
Discussion
We found predicted pathogenic (protein-affecting) 
germline variants in known cancer-predisposing DNA 
repair genes (including PALB2, MSH2, ATR, NBN, and 
RECQL5) in six (27%) of 22 families with hereditary 
diffuse gastric cancer. This finding reflects the increasing 
number of cancer phenotypes found to be associated 
with existing cancer-predisposing genes as genomic 
analyses extend to rarer cancer subtypes. For example, 
mismatch repair genes were initially associated with 
increased risk of colorectal cancer, but were subsequently 
associated with risk of developing gastric and pancreatic 
cancers, among others.21,22
Simply identifying predicted pathogenic variants in 
known cancer-predisposing genes does not imply 
causality. For example, pathogenic germline variants in 
MSH2 were not accompanied by altered expression of 
DNA mismatch repair proteins in tumour tissue in our 
study. To investigate causality, larger studies with 
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cancer
Gastric
cancer
Breast
cancer
Diffuse
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cancer
 (44)
Diffuse
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cancer 
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PALB2+/+
1 2 3
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Figure 2: Pedigree and cancer history for family 4 
(A) Whole-exome sequencing was done on the three circled individuals; age at diagnosis of cancer is shown in parentheses when known. (B) Chromatograms 
showing the PALB2 frameshift variant (c.757-758TAG→T) in DNA from individuals 1 and 2 compared with control DNA. 
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matched controls are required, which is not typically 
feasible for rare diseases. The generation of large control 
datasets, such as ExAC and 1000 Genomes, can be used 
to strengthen possible associations, as we have shown in 
the case of PALB2. When combining our data with 
those from previously published relevant studies,4,10,16,17 
including those in which no PALB2 variants were found, 
we saw a significant over-representation of PALB2 
(but not BRCA2) pathogenic variants in families with 
hereditary diffuse gastric cancer compared with ExAC 
and 1000 Genomes controls; however, this finding 
was much less significant when comparing with the 
503 Europeans in the 1000 Genomes Project set than 
when comparing with the 27 173 individuals from the 
non-Finnish, non-TCGA ExAC dataset.15
In several of the cases described by Sahasrabudhe and 
colleagues,10 tumour molecular profiling was done and 
showed that carriers of PALB2 mutations had mutational 
signatures indicative of defects in homologous recomb-
ination. PALB2 has an important role in homologous 
recombination during double-stranded DNA break repair 
through recruitment of BRCA2 and RAD51 to DNA 
breaks. Mutations in this gene are associated with an 
increased risk of breast and pancreatic cancers.23–25 Even 
within families carrying PALB2 mutations, cases of diffuse 
gastric cancer are likely to be rare and could be masked by 
a larger number of sporadic gastric adenocarcinomas, 
which means that associations with certain cancer 
subtypes might be missed in epidemiological studies of 
these families unless the pathology of all reported cancers 
is known. For example, a recent study26 revealed that a rare 
serous subtype of endometrial cancer is over-represented 
in carriers of BRCA1 variants, identifying a novel cancer 
association with a gene that has been intensively studied 
for more than 20 years.
ATR and NBN are also involved in initiating the 
response to double-strand DNA breaks. The NBN gene 
product (NBS1) associates with MRE11 and RAD50 to 
form a complex involved in the activation of the ataxia 
proteins ATM and ATR, which have roles in the 
recruitment of damage repair proteins, cell cycle 
regulation, and apoptosis. We identified single 
loss-of-function variants in NBN or ATR in the parents of 
the proband in family 11, both of whom had, or were 
suspected to have, diffuse gastric cancer. These variants 
were co-inherited in all three siblings in the family. 
Expression of either one of these variants might 
predispose family members to diffuse gastric cancer, 
although no other incidences of gastric cancer, and only 
one instance of late-onset prostate cancer, were noted in 
an extensive maternal and paternal family history. Slavin 
and colleagues17 also identified a stop site-gain variant in 
ATR in an individual with intestinal-type adenocarcinoma 
and a strong family history of gastric cancer.
The unusual cancer pattern seen in family 11 (with all 
immediate family members [siblings and parents], but 
no extended family members, of the proband affected) 
might be attributed to multi-locus, inherited neoplasia 
alleles syndrome, in which inheritance of pathogenic 
mutations in multiple cancer-predisposing genes leads 
to an atypical or severe phenotype.27 The close functional 
relationship between NBN and ATR in double-stranded 
Diffuse gastric
cancer (60)
Diffuse gastric
cancer (28)
Individual 2
Control
Individual 2
Control
A A A A A AT T T TC CG G G
A A A A A AT T T TC CG G G
ATT T T TT TTTTTC CG
AATT T T T TTTTTC CG
Gastric cancer (45) 
Signet-ring
cells
Signet-ring
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NBN+/+, ATR+/–
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Figure 3: Pedigree and cancer history of family 11
(A) Whole-exome sequencing was done on the three circled individuals; the 
proband was patient 4. The presence of the variants in NBN (c.1124+1G→C) and 
ATR (c.6075A→T) among the four affected family members are shown. Age at 
diagnosis of cancer is shown in parentheses when known. *DNA was not 
available for the mother, and so the mother’s genotype was assumed on the 
basis of the genotypes of the father and children. †These individuals underwent 
risk-reducing gastrectomies. (B) Chromatograms showing the NBN variants in 
DNA from individual 2 compared with control DNA. (C) Chromatograms 
showing the ATR variants in DNA from individual 2 compared with control DNA. 
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DNA break repair could indicate a potential combinatorial 
effect of variants in these genes, as potentially suggested 
by the young age of diagnoses or the presence of 
signet-ring cells in the siblings carrying these variants. 
By contrast, double heterozygosity of mutations in the 
DNA repair genes BRCA1 and BRCA2 in patients with 
breast cancer was found to be no more deleterious 
than a single heterozygous mutation.28 Nevertheless, 
such double heterozygosity might have implications for 
genetic counselling that should be considered.
Genetic variants in genes involved in the mismatch 
DNA repair pathway are also associated with Lynch 
syndrome. A variant similar to the start-site loss variant 
that we identified in MSH2 (c.1A→G) has previously 
been shown to have only a mild effect on protein 
function;29 thus, this variant should not be treated as a 
typical loss-of-function variant. This attenuated effect on 
protein function could be due to the presence of an 
alternative start codon and a second non-mutated MSH2 
allele. Increased microsatellite instability, a measure of 
decreased MSH2 function, has been shown in patients 
and tumours with the c.1A→G start site-loss variant.29 
However, in tumours from both cases analysed here, 
MSH2 expression (detected by immunohistochemistry 
staining) was normal and no microsatellite instability 
was found. Although it is most likely that tumorigenesis 
was not caused by mismatch repair deficiency, we 
cannot rule out the possibility of a novel, non-mismatch 
repairmediated mechanism of carcinogenesis driven by 
variants in MSH2.
The helicase RECQL5 is important for prevention of 
aberrant homologous recombination and accumulation 
of double-strand DNA breaks, and thus for preservation of 
genome stability.30 A missense RECQL5 variant was 
identified in the proband from family 21, and was not 
found in the proband’s unaffected father. A splice-acceptor 
variant in RECQL5 was identified in an individual in 
family 6 who was diagnosed with diffuse gastric cancer at 
age 37 years. Both family 6 and family 21 had a history of 
breast and gastric cancer.
Previous studies have explored the role of known 
cancer predisposition genes in individuals with 
hereditary diffuse gastric cancer who do not have 
known CDH1 mutations. Sahasrabudhe and colleagues10 
identified germline variants in PALB2, BRCA1, and 
RAD51C in families with diffuse gastric cancer. Hansford 
and colleagues4 described variants in ATM, BRCA2, 
MSR1, and STK11, as well as a frameshift deletion in 
PALB2. This group has also uncovered a role for the 
CDH1-related adhesion gene CTNNA1. Although we did 
not find any variants of interest in ATM, BRCA1, BRCA2, 
CTNNA1, MSR1, RAD51C, or STK11, an exploration of 
PALB2 variants in all families with hereditary diffuse 
gastric cancer sequenced in recent studies showed 
enrichment of loss-of-function variants in these families 
compared with control datasets. This finding makes a 
case for inclusion of PALB2 in genetic testing for 
families with hereditary gastric cancer without CDH1 
mutations, and it is possible that individuals who carry 
PALB2 mutations might benefit from platinum-based 
chemo therapy and treatment with PARP inhibitors.31 
However, the evidence is not yet sufficient to recommend 
surveillance of diffuse gastric cancer in carriers of 
PALB2 mutations because the absolute risk is likely to 
be low in the absence of a family history.
Sporadic stomach cancers have been analysed as part of 
the TCGA study,32 and an association was identified 
between truncating PALB2 mutations and sporadic 
stomach adenocarcinoma. Of the individuals with sporadic 
stomach adenocarcinoma and PALB2 mutations from the 
TCGA database, we selected 88 individuals with diffuse 
gastric cancer, as described by Bass and colleagues,33 
among which we did not identify any truncating PALB2 
variants. However, the average age at diagnosis for this 
cohort was 66 years, so this finding is perhaps not 
unexpected given the younger age of onset usually 
observed in hereditary cancers.
The rarity of patients with hereditary diffuse gastric 
cancer without pathogenic CDH1 variants makes the 
collection of large datasets challenging. We used 
Race Patient ID Diagnosis of proband (age at 
diagnosis in years)
Variant Consequence Protein change
Hansford et al (2015)4 European P124 Diffuse gastric cancer (45) c.1193AC→A fs deletion Val398fs
Sahasrabudhe et al (2017)10 European CG-12 Intestinal gastric cancer (69) c.1240C→T Stop-site gain Arg414Ter
Sahasrabudhe et al (2017)10 European CG-008 Diffuse gastric cancer (48) c.1240C→T Stop-site gain Arg414Ter
Sahasrabudhe et al (2017)10 European GM037589 Gastric cancer (46) c.1240C→T Stop-site gain Arg414Ter
Sahasrabudhe et al (2017)10 European CG-05 Diffuse gastric cancer (50) c.3201+1G→T Splice-site variant NA
Sahasrabudhe et al (2017)10 European CG-039 Diffuse gastric cancer (47) c.1882_1890delAAGTCCTGC In-frame deletion Lys628_Cys630del
Sahasrabudhe et al (2017)10 Latin American CG-028 Intestinal gastric cancer (81) c.1882_1890delAAGTCCTGC In-frame deletion Lys628_Cys630del
Sahasrabudhe et al (2017)10 Latin American 3CG-103 Mixed (79) c.2753C→A Missense Pro918Gln
Fewings et al (this study) European GST_172_301 Diffuse gastric cancer (55) c.757_758TAG→T fs deletion Leu253fs
Teixeira (unpublished) European GM048157 Diffuse gastric cancer (56) c.1438A→T Stop-site gain Lys480Ter
None of the identified PALB2 variants appeared in the 1000 Genomes Project European samples or in the Exome Aggregation Consortium European datasets. fs=frameshift. NA=not applicable.
Table 3: PALB2 variants identified in hereditary diffuse gastric cancer sequencing studies
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gene-interaction network analysis to prioritise candidate 
gene variants that co-segregated with disease phenotype 
and were likely to be involved in predisposition to 
hereditary diffuse gastric cancer on the basis of 
knowledge of the biology of the disease. This approach 
did not overcome the problem of low statistical power 
due to a small sample size, which is often seen with rare 
cancer datasets, but it did allow for selection of the most 
plausible candidates from the available data.
We attempted an additional analysis of copy number 
variants within this dataset using the XHMM algorithm.11 
Although this analysis did not suggest any plausible 
candidates, at present, copy number variant analysis of 
germline whole-exome sequencing data is not validated 
and, therefore, some causal copy number variants could 
have been missed.
In summary, we found that rare, protein-affecting 
variants in DNA damage repair genes were enriched in 
families with hereditary diffuse gastric cancer without 
pathogenic CDH1 variants compared with control 
datasets. Further studies of these genes in similar 
families are required to increase knowledge of the 
genetic basis of hereditary diffuse gastric cancer so that 
better informed decisions about risk reduction and 
management in affected family members can be made. 
Lastly, for many families with hereditary diffuse gastric 
cancer without pathogenic CDH1 variants, the underlying 
cause remains unexplained even after whole-exome 
sequencing, and although whole-genome sequencing 
might identify some additional candidates in regulatory 
elements or structural variants, it seems unlikely that 
high-impact genes other than CDH1 will be implicated in 
hereditary diffuse gastric cancer. Therefore, focusing on 
moderate-impact or low-impact cancer genes, such as 
PALB2, might be the way forward for future studies 
of genes associated with predisposition to disease in 
these patients.
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